Over 60 Leading Finance Economists Ask SEC to Revise the Shareholder Voting Draft Reform

The new regulation that Security and Exchange Commissioners voted in November doesn’t fix proxy advisory industry duopoly problems, but it actually makes them worse: A group of scholars from major American universities filed a comment to ask the SEC to amend the proposed reform of public companies corporate governance.    

Read more

New Rules on Shareholder Voting Debate: Best Readers’ Comment

The draft SEC regulation on shareholder proposal and proxy advisory firms will curb the initiative of individual shareholders to improve corporate governance and transparency of public firms, a ProMarket reader writes in the comment he sent to the SEC. “Progress on best practices often depends on the initiative of a few.” 

Read more

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

Purdue’s strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and consumers through an apparently independent entity called “Partners Against Pain,” but ultimately controlled by the company itself. 

Read more

Who Benefits When State Governments Award Incentives to Politically-Connected Companies?

A new study finds that a company is nearly four times more likely to receive an economic incentive in a state where the company makes political contributions to state-level candidates. The results also show that awarding economic incentives to politically-connected firms is not the most effective use of taxpayer funds. 

Read more

Purdue Circumvented the Regulator to Promote OxyContin, Hiding Its Real Risk of Addiction

In 2001, the Food and Drug Administration required Purdue to change OxyContin’s patient package inserts to make addiction risks more evident. The company altered the label to make it appear as though illegal use and abuse were the only addiction-related problems associated with OxyContin. Eventually, Purdue hired the FDA’s medical reviewer for OxyContin. 

Read more

“You Can Put the Monopoly Tiger in a Cage but You Cannot Transform a Tiger Into a Vegan”

In an extensive interview with the Swiss news website TheMarket.ch, Luigi Zingales discusses ways to deal with Big Tech and the impact of the antitrust debate on the 2020 presidential election and on consumer welfare. “The digital economy is substantially different from a traditional textbook economy.”

Read more

OxyContin’s Academic Marketing: The Studies That Fueled the Opioid Crisis

Purdue Pharmaceuticals used to cite three major studies to argue that in prescribing OxyContin, addiction-risk was not significant. The most influential of those studies did not even mention OxyContin, because it was completed twenty-five years before OxyContin was sold. After more than a decade, the company had to admit that “data are not available to establish the true incidence of addiction.”

Read more
1 2 3 15